Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Conmed (CNMD) EBIT (2016 - 2026)

Conmed filings provide 17 years of EBIT readings, the most recent being $25.4 million for Q1 2026.

  • On a quarterly basis, EBIT rose 59.26% to $25.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $112.1 million, a 38.17% decrease, with the full-year FY2025 number at $102.6 million, down 48.77% from a year prior.
  • EBIT hit $25.4 million in Q1 2026 for Conmed, down from $36.6 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $65.7 million in Q3 2024 to a low of -$1.1 million in Q4 2022.
  • Median EBIT over the past 5 years was $27.4 million (2023), compared with a mean of $30.5 million.
  • Biggest five-year swings in EBIT: plummeted 102.94% in 2022 and later skyrocketed 4683.29% in 2023.
  • Conmed's EBIT stood at -$1.1 million in 2022, then skyrocketed by 4683.29% to $50.2 million in 2023, then grew by 4.61% to $52.5 million in 2024, then tumbled by 30.24% to $36.6 million in 2025, then crashed by 30.61% to $25.4 million in 2026.
  • The last three reported values for EBIT were $25.4 million (Q1 2026), $36.6 million (Q4 2025), and $11.9 million (Q3 2025) per Business Quant data.